This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
https://awmsg.nhs.wales/
.
Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
triptorelin (Decapeptyl® SR)
Reference No. 1658
Publication date:
14/03/2017
Appraisal information
triptorelin (Decapeptyl® SR) 22.5 mg powder and solvent for suspension for injection
triptorelin (Decapeptyl® SR) 11.25 mg powder for suspension for injection
triptorelin (Decapeptyl® SR) 3 mg powder for suspension for injection
Company:
Ipsen Ltd
BNF category:
Malignant disease and immunosupression
NMG meeting date:
11/01/2017
AWMSG meeting date:
15/02/2017
Submission Type:
Limited Submission
Status:
Recommended
Advice No:
0417
Ratification by Welsh Government:
14/03/2017
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Triptorelin (Decapeptyl® SR) is recommended as an option for use within NHS Wales as an adjuvant treatment to radiotherapy in patients with high risk localised or locally advanced prostate cancer and as neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
Final Appraisal Recommendation (FAR)
Download
triptorelin (Decapeptyl SR) 1658 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
triptorelin (Decapeptyl SR) 1658 ASAR
Clinical Expert (CE) Summary
Download
triptorelin (Decapeptyl SR) 1658 CE summary
